THERAPEUTIC APPLICATIONS OF SOLID LIPID EMULSIONS CONTAINING THE NATURAL COMPONENTS CURCUMIN AND PIPERIN
Patent Information
- Application Number
- TR201905678
- Authority / Receiving Office
- TR · TR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2019-04-16
- Publication Date
- 2026-10-21
- Estimated Expiration
- 2039-04-16
AI Technical Summary
Existing formulations of curcumin and piperine suffer from low drug loading capacity, toxicity due to organic solvents and surfactants, rapid drug release, and insufficient cellular uptake, leading to suboptimal therapeutic effects in treating neoplastic diseases.
Development of emulsomes with a phospholipid layer and triglyceride core, free from organic solvents and surfactants, allowing high drug loading and controlled release of curcumin and piperine, enhancing cellular uptake and targeting capabilities.
The emulsomes provide enhanced bioavailability and prolonged action of curcumin and piperine, improving therapeutic efficacy against neoplastic diseases by increasing cellular uptake and reducing toxicity.
Abstract
Description
DESCRIPTION THERAPEUTIC APPLICATIONS OF SOLID LIPID EMULSIONS CONTAINING NATURAL COMPONENTS OF CURCUMIN AND PIPER TECHNICAL FIELD The present invention relates to solid lipid emulsion formulations (emulsomes) containing the natural components curcumin and piperine and the use of said emulsomes in the treatment of neoplastic diseases. KNOWN STATE OF TECHNOLOGY Curcumin is the main ingredient of the turmeric plant, and piperine is the main ingredient of the black pepper plant. The various therapeutic effects of these two natural active compounds have been known from ancient civilizations to the present day. In modern medical practice, their use has been investigated, particularly in recent years, and their effectiveness against certain disease models (such as various types of cancer and Alzheimer's disease) has been observed. Curcumin (turmeric), in particular, offers great potential due to its anti-inflammatory, anti-carcinogenic, antibacterial, antirheumatic, and regenerative properties. However, curcumin's insufficient water solubility and instability (rapid breakdown into subcomponents) in water hinder its use in therapeutic applications. Curcumin's absorption is low, and even at high doses (e.g., 810 mg per day), its blood concentration remains well below therapeutic levels.This situation results in the inability to deliver sufficient amounts of curcumin to the tissue where the health problem is located. Studies have shown that the combined use of piperine, an active ingredient found in black pepper (piper nigrum), and turmeric produces a synergistic effect by increasing the solubility and bioavailability of turmeric. Accordingly, the combined use of curcumin and piperine results in formulations with higher bioavailability. Considering the current state of the art, it appears that in order to obtain maximum benefit from curcumin, various nanocarrier systems are needed that increase the absorption of this substance, especially in the intestines and / or enable its injection directly into the blood. Various studies have been conducted to develop formulations with these properties, focusing on the synergistic delivery of curcumin and piperine molecules on various macromolecular platforms such as liposomes, micelles, solid lipid nanoparticles, polymers, and dendrimers. However, such formulations have been plagued by problems such as low drug loading capacity, undesirable toxicity and side effects due to the organic solvent and surfactant used in the formulation preparation, low stability, inadequate cellular uptake, rapid drug release, and high economic costs. The inventors aim to overcome these existing problems in the state of the art, particularly the toxicity associated with the use of surfactants, and to develop an alternative curcumin-piperine formulation to these existing formulations. BRIEF DESCRIPTION OF THE INVENTION The invention relates to emulsomes consisting of a phospholipid layer and a triglyceride solid core in which piperine and curcumin are dispersed, and the use of said emulsomes in the treatment of neoplastic diseases. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to pharmaceutical formulations containing piperine and curcumin and is characterized by; It is in the form of an emulsome, with a core made up of triglyceride derivatives and an outer layer made up of phospholipids, and containing cholesterol or ester derivatives in both its core and outer layer. In their studies, the inventors found that curcumin and piperine formulations formulated in emulsomes with the properties given above have the advantages of (i) not having toxic effects due to not containing organic solvents and surfactants in their structure; (ii) allowing high amounts of curcumin and piperine to be loaded into the structure; (iii) extending the effect time of curcumin and piperine by increasing the release time thanks to their unique solid phase structure; and (iv) enabling the preparation of curcumin and piperine formulations whose release or absorption properties are changed or whose targeted effects are achieved by binding molecules such as proteins, polymers, various targeting ligands, etc., thanks to the modifiable structures of the phospholipids forming the outer surface of the emulsomes. In one embodiment of the invention, the triglyceride derivatives that form the core of the emulsome formulations containing curcumin and piperine according to the invention are selected from a group consisting of oils that are in solid or liquid crystalline form at 25 ° C, natural, even-numbered, unbranched triglycerides such as tricaprine, trilaurin, trimyristin, tripalmitin and tristearin, monounsaturated fatty acids, and partially hydrogenated vegetable oils. In a preferred embodiment of the invention, tripalmitin, also known as triglyceride palmitate, is used as the triglyceride derivative substance that forms the core of the emulsome formulations containing curcumin and piperine. In one embodiment of the invention, the phospholipids forming the outer surface of the emulsome formulations containing curcumin and piperine can be selected from natural phospholipids such as soy lecithin, egg lecithin, phosphatidyl glycerol, phosphatidyl inostol, phosphatidyl ethanolamine, phosphatidic acid, sphingomyelin, di phosphatidylglycerol, phosphatidyl serine, phosphatidyl choline, cardiolipin or synthetic phospholipids such as dimyristoyl phosphatidylglycerol, dimyristoyl phosphatidylcholine, 1,2dipalmitol-rac-glycero-3- phosphatidylcholine (DPPC) or from a group consisting of hydrogenated or partially hydrogenated lecithins and phospholipids. In a preferred embodiment of the invention, 1,2dipalmitol-rac-glycero-3- phosphatidylcholine (DPPC) is used as the phospholipid. In one embodiment of the invention, the cholesterol found in the core and outer layer of emulsome formulations containing curcumin and piperine is selected from a group consisting of cholesterol, palmitoyl cholesterol, oleoyl cholesterol. In one embodiment of the invention, the weight ratio of triglyceride, phospholipid and cholesterol derivatives forming the emulsome structure to each other (triglyceride:phospholipid:cholesterol) is in the range of 17:1:1 to 21:3:1, preferably in the range of 18:1.5:1 to 20:2:1. Accordingly, in a preferred embodiment of the invention, the present invention is directed to pharmaceutical formulations containing curcumin and piperine, and is characterized as follows; The core consists of triglyceride palmitate, the outer layer consists of 1,2-dipalmitol-rac-glycero-3-phosphatidylcholine (DPPC), and it is in the form of an emulsome with cholesterol in both the core and the outer layer. In one embodiment of the invention, the weight ratio of triglycerin palmitate, 1,2dipalmitol-rac-glycero-3-phosphatidylcholine (DPPC) and cholesterol forming the emulsome structure to each other (triglycerin palmitate:DPPC:cholesterol) is in the range of 17:1:1 to 21:3:1, preferably in the range of 18:1.5:1 to 20:2:1. Accordingly, in a particularly preferred embodiment of the invention, the present invention is directed to pharmaceutical formulations containing curcumin and piperine, and is characterized by; The core is composed of triglycerin palmitate and the outer layer is composed of 1,2-dipalmitol-rac-glycero-3-phosphatidylcholine (DPPC) and is in the form of an emulsome with cholesterol in both the core and outer layer, and the triglycerin palmitate:DPPC:cholesterol ratio is between 17:1:1 and 21:3:1, preferably between 18:1.5:1 and 20:2:1. One embodiment of the invention relates to a method to be used in the preparation of emulsomes containing curcumin and piperine according to the invention, said method; dissolving triglyceride, phospholipid and cholesterol derivatives in an organic solvent, preferably chloroform dissolving curcumin and piperine in an organic solvent, preferably chloroform Film structure is obtained by mixing the obtained solutions and removing the organic solvent under low pressure. It includes the steps of obtaining emulsome formulations containing curcumin and piperine by dissolving the resulting film structure in water. In a preferred embodiment of the invention, the emulsome formulation containing curcumin and piperine is subjected to a sonication bath, filtration (extrusion) or homogenization process in order to homogenize the particle size distribution of the emulsomes constituting the formulation. In a preferred embodiment of the invention, the organic solvent, preferably chloroform, can be removed at room temperature or at a temperature between 40-60 °C. In another aspect, the invention is directed to the use of emulsome formulations containing curcumin and piperine according to the invention as medicines for the treatment of neoplastic diseases. The term "neoplastic diseases," as used within the scope of the present invention, refers to malignant tumors or a physiological condition characterized by uncontrolled cell growth, such as cancer. Within the scope of the invention, the terms "neoplastic disease" and "cancer" are used interchangeably. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. Carcinoma, as used here, refers to a type of cancer that consists of epithelial cells. Lymphoma, as used here, describes a type of cancer that develops from lymphocytes. Blastoma, as used here, describes a type of cancer that develops from precursor cells, also known as blast cells. Sarcoma, as used here, describes a type of cancer arising from transformed cells of mesenchymal origin. Leukemia, as used here, refers to a type of cancer that begins in the bone marrow and causes the formation of large numbers of abnormal white blood cells. More specific examples of cancer types include breast cancer, prostate cancer, colorectal cancer, skin cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, gastrointestinal cancer, pancreatic cancer, glioblastoma, vulvar cancer, cervical cancer, endometrial carcinoma, ovarian cancer, liver cancer, hepatoma, bladder cancer, kidney cancer, salivary gland carcinoma, thyroid cancer, and various head and neck cancers. In the context of this specification, the term includes is intended to indicate includes. Where technically feasible, embodiments of the invention may be combined. The embodiments are described herein as comprising certain features / elements. The specification also encompasses other embodiments that consist essentially of or consist of the aforementioned features / elements. Technical references such as patents and applications are incorporated into this document by reference. The applications specifically and expressly described herein may constitute a disclaimer alone or in combination with one or more other applications. The invention will now be described with reference to the following examples, which are for illustrative purposes only and are not to be construed as limiting the scope of the invention in any way. EXAMPLES: Example 1: Preparation of Emulsomes Containing Piperine and Curcumin Table 1: Emulsome constituents and their quantities Molecular Weight (g / mol) Amount (mg) Mass Fraction Mole Fraction Tripalmitin 807.34 20 0.87 0.82 DPPC 734.04 2 0.09 0.09 Cholesterol 386.66 1.04 0.04 0.09 Tripalmitin, DPPC, and cholesterol were dissolved in chloroform in the amounts listed in Table 1. Separately, curcumin and piperine were dissolved in chloroform. The two resulting mixtures were combined, and the chloroform, used as the solvent, was removed at 60°C under reduced pressure. By dissolving the resulting film in water, emulsome formulations containing piperine and curcumin are obtained. Then, optionally, sonication, filtration (extrusion) or homogenization is applied to ensure that the size of the emulsomes obtained is homogeneous. Example 2: Cell Viability Test with HCT116 Cells Cell viabilities of HCT116 cells after treatment with curcumin- and piperine-loaded emulsomes were determined using the MTS cell viability technique. In the assay performed using 96-well plates, 10,000 cells were seeded per well for the HCT116 cell line. After observation of cell settlement, they were treated with 2.8 μΜ piperine-loaded emulsome and 25 μΜ curcumin-loaded emulsome, separately and together. Untreated cells were used as negative controls. After 24, 48, and 72 hours of treatment, cells were treated with the colorimetric cell agent MTS (“CellTiter96 AQueousOne Solution Cell Proliferation Assay”) (Figure 1). After two hours of incubation in the dark, the absorbance values of the cells at 490 nm were measured using a microplate spectrophotometer. This procedure was repeated at 24, 48, and 72 hours.The analysis of the results was calculated by assuming the viability of the negative control cells as 100%. The cell viability rates obtained for HCT116 cells are shown in the graph in Figure 1. Accordingly, while cell viability in cells treated with only piperine-loaded emulsome did not differ from the control group, cell viability in cells treated with curcumin-loaded emulsome was 65% at 48 hours and 49% at 72 hours. These values were determined as 56% and 46% for cells treated with curcumin plus piperine-loaded emulsomes. A significant difference was observed between the HCT116 cells treated with curcumin and piperine-loaded emulsomes and the control group. Explanations of Figures: Figure 1 shows the effect of 2.8 μΜ piperine-loaded emulsome (PE) and 25 μΜ curcumin-loaded emulsome (KE) and their combinations (25 μΜ KE + 2.8 μΜ PE) on HCT116 cell viability, respectively.
Claims
CLAIMS 1. It relates to pharmaceutical formulations containing piperine and curcumin and its feature is that it is in the form of an emulsome with a core made of triglyceride derivatives, an outer layer made of phospholipids and cholesterol or ester derivatives in both its core and outer layer.
2. A formulation according to claim 1, characterized in that the triglyceride derivatives are selected from a group consisting of oils that are in solid or liquid crystalline form at 25 ° C, natural, even-numbered, unbranched triglycerides such as tricaprine, trilaurin, trimyristin, tripalmitin and tristearin, mono-unsaturated fatty acids, and partially hydrogenated vegetable oils.
3. A formulation according to claim 2, characterized in that the triglyceride derivative is tripalmitin.
4. A formulation according to claims 1-3, characterized in that the phospholipids are selected from natural phospholipids such as soy lecithin, egg lecithin, phosphatidyl glycerol, phosphatidyl inostol, phosphatidyl ethanolamine, phosphatidic acid, sphingomyelin, di phosphatidylglycerol, phosphatidyl serine, phosphatidyl choline, cardiolipin or synthetic phospholipids such as dimyristoyl phosphatidylglycerol, dimyristoyl phosphatidylcholine, 1,2-dipalmitol-rac-glycero-3- phosphatidylcholine (DPPC) or from a group consisting of hydrogenated or partially hydrogenated lecithins and phospholipids.
5. A formulation according to claim 4, characterized in that the phospholipid is 1,2-dipalmitol-racglycero-3-phosphatidylcholine (DPPC).
6. A formulation according to claims 1-5, characterized in that cholesterol or its ester derivatives are selected from a group consisting of cholesterol, palmitoyl cholesterol, oleoyl cholesterol.
7. A formulation according to claim 6, characterized in that the cholesterol or ester derivatives are cholesterol.
8. A formulation according to claims 1-7, characterized in that the weight ratio of triglyceride, phospholipid and cholesterol derivatives forming the emulsome structure to each other (triglyceride: phospholipid: cholesterol) is in the range of 17:1:1 to 21:3:1, preferably in the range of 18:1.5:1 to 20:2:
1.
9. A formulation according to claims 1-8, characterized in that; - the core is composed of triglycerin palmitate and the outer layer is composed of 1,2-dipalmitol-rac-glycero-3-phosphatidylcholine (DPPC) and it is in the form of an emulsome with cholesterol in both its core and outer layer, and the triglycerin palmitate:DPPC:cholesterol ratio is in the range of 17:1:1 to 21:3:1, preferably in the range of 18:1.5:1 to 20:2:
1.
10. A method to be used in obtaining a formulation according to claims 1-9, and its feature is that it includes the steps of; dissolving triglyceride, phospholipid and cholesterol derivatives in an organic solvent, preferably chloroform, dissolving curcumin and piperine in an organic solvent, preferably chloroform, mixing the obtained solutions and obtaining the film structure by removing the organic solvent under low pressure, and dissolving the obtained film structure in water to obtain emulsome formulations containing curcumin and piperine.
11. A method according to claim 10, characterized in that the emulsome formulation containing curcumin and piperine is subjected to a sonication bath, filtration (extrusion) or homogenization process.
12. Use of the emulsome formulation containing piperine and curcumin according to claims 1-9 as a medicament for the treatment of neoplastic diseases.
13. A use according to claim 12, wherein the neoplastic disease is cancer.
14. The use of claim 13, wherein the cancer may be carcinoma, lymphoma, blastoma sarcoma, or leukemia.
15. The use of claim 14, wherein the cancer may be breast cancer, prostate cancer, colorectal cancer, skin cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, gastrointestinal cancer, pancreatic cancer, glioblastoma, vulvar cancer, cervical cancer, endometrial carcinoma, ovarian cancer, liver cancer, hepatoma, bladder cancer, kidney cancer, salivary gland carcinoma, thyroid cancer, and various head and neck cancers.
